Bone health in phenylketonuria: A systematic review and meta-analysis

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Demirdas, Serwet ^a   Coakley, Katie E ^b   Bisschop, Peter H ^a   Hollak, Carla E M ^a   Bosch, Annet M ^a   Singh, Rani H ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMD; Bone mineral density; Bone turnover markers; Meta analysis; Osteopenia; Osteoporosis; Phenylalanine; Phenylketonuria; PKU; Systematic review

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; MAGNESIUM; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHENYLALANINE; VITAMIN D;

BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CORTICAL BONE; DIETARY COMPLIANCE; DIETARY INTAKE; FEMUR NECK; FOOD INTAKE; FRACTURE; HUMAN; LEAN BODY WEIGHT; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHENYLKETONURIA; PHOSPHATE BLOOD LEVEL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRABECULAR BONE; AGING; COMPLICATION; PHYSIOLOGY;

AGING; BONE DENSITY; FRACTURES, BONE; HUMANS; PHENYLKETONURIAS;

EID: 84928730941     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0232-y     Document Type: Review

References (53)

1. Blau N, Belanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, et al. Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010;99:109-15.
2. van Spronsen FJ, Burgard P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis. 2008;31:673-9.
3. Demirkol M, Gizewska M, Giovannini M, Walter J. Follow up of phenylketonuria patients. Mol Genet Metab. 2011;104(Suppl):S31-9.
4. Robert M, Rocha JC, van Rijn M, Ahring K, Belanger-Quintana A, MacDonald A, et al. Micronutrient status in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S6-17.
5. Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, et al. Phenylketonuria scientific review conference: state of the science and future research needs. Mol Genet Metab. 2014;112:87-122.
6. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417-27.
7. Harding CO, Blau N. Advances and challenges in phenylketonuria. J Inherit Metab Dis. 2010;33:645-8.
8. Giovannini M, Verduci E, Salvatici E, Paci S, Riva E. Phenylketonuria: nutritional advances and challenges. Nutr Metab (Lond). 2012;9:7.
9. Feinberg SB, Fisch RO. Roentgenologic findings in growing long bones in phenylketonuria. Preliminary study. Radiology. 1962;78:394-8.
10. Murdoch MM, Holman GH. Roentgenologic bone changes in phenylketonuria. Relation to dietary phenylalanine and serum alkaline phosphatase. Am J Dis Child. 1964;107:523-32.
11. Porta F, Spada M, Lala R, Mussa A. Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study. Ultrasound Med Biol. 2008;34:1049-52.
12. Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schönau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr. 1998;87:61-3.
13. Adamczyk P, Morawiec-Knysak A, Pludowski P, Banaszak B, Karpe J, Pluskiewicz W. Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria. J Bone Miner Metab. 2011;29:236-44.
14. de Groot MJ, Hoeksma M, van Rijn M, Slart RH, van Spronsen FJ. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol Genet Metab. 2012;105:566-70.
15. Lage S, Bueno M, Andrade F, Prieto JA, Delgado C, Legarda M, et al. Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. J Inherit Metab Dis. 2010;33 Suppl 3:363-71.
16. Zeman J, Bayer M, Stepan J. Bone mineral density in patients with phenylketonuria. Acta Paediatr. 1999;88:1348-51.
17. Allen JR, Humphries IR, Waters DL, Roberts DC, Lipson AH, Howman-Giles RG, et al. Decreased bone mineral density in children with phenylketonuria. Am J Clin Nutr. 1994;59:419-22.
18. Hansen KE, Ney D. A systematic review of bone mineral density and fractures in phenylketonuria. J Inherit Metab Dis. 2014;37(6):875-80.
19. Roato I, Porta F, Mussa A, D'Amico L, Fiore L, Garelli D, et al. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS One. 2010;5:e14167.
20. Mendes AB, Martins FF, Cruz WM, da Silva LE, Abadesso CB, Boaventura GT. Bone development in children and adolescents with PKU. J Inherit Metab Dis. 2012;35:425-30.
21. Nagasaka H, Tsukahara H, Takatani T, Sanayama Y, Takayanagi M, Ohura T, et al. Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening. J Bone Miner Metab. 2011;29:737-43.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint-preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89:873-80.
23. Coakley KE. A systematic review of bone health in phenylketonuria (PKU). PROSPERO Centre for reviews and dissemination. 2014. [http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42014009176#. U4WEqO0ayc0]
24. Wright RW, Brand RA, Dunn W, Spindler KP. How to write a systematic review. Clin Orthop Relat Res. 2007;455:23-9.
25. Singh RH, Rohr F, Splett PL. Bridging evidence and consensus methodology for inherited metabolic disorders: creating nutrition guidelines. J Eval Clin Pract. 2013;19:584-90.
26. Cochrane Renal Group Editorial Team. Cochrane renal group protocol guidelines: how to write a protocol. 2010. [http://www.cochrane-renal.org/docs/how%20to%20write%20a%20protocol.pdf]
27. Rauch F, Plotkin H, Di Meglio L, Engelbert RH, Henderson RC, Munns C, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom. 2008;11:22-8.
28. Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj FG, Kecskemethy HH, et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014;17:225-42.
29. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23-57.
30. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007;83:509-17.
31. Engelke K, Gluer CC. Quality and performance measures in bone densitometry: part 1: errors and diagnosis. Osteoporos Int. 2006;17:1283-92.
32. American Dietetic Association Scientific Affairs & Research. ADA evidence analysis manual. 2008. [https://www.adaevidencelibrary.com/vault/editor/File/Evidence-Analysis-Manual-January-2008.pdf]
33. Singh RH, Rohr F, Frazier D, Cunningham A, Mofidi S, Ogata B, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med. 2014;16:121-31.
34. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-6.
35. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
36. Miras A, Boveda MD, Leis MR, Mera A, Aldamiz-Echevarria L, Fernandez-Lorenzo JR, et al. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab. 2013;108:149-54.
37. Hillman L, Schlotzhauer C, Lee D, Grasela J, Witter S, Allen S, et al. Decreased bone mineralization in children with phenylketonuria under treatment. Eur J Pediatr. 1996;155 Suppl 1:S148-52.
38. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
40. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
41. National Health and Nutrition Examination Survey. NHANES 2007-2008 examination data. 2014. [http://wwwn. cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Examination&CycleBeginYear=2007]
42. Looker AC, Borrud LG, Hughes JP. Total body bone area, bone mineral content, and bone mineral density for individuals aged 8 years and over: United States, 1999-2006. National Center for Health Statistics Vital Health Stat. 2013, series 11, number 253.
43. Barat P, Barthe N, Redonnet-Vernhet I, Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur J Pediatr. 2002;161:687-8.
44. Modan-Moses D, Vered I, Schwartz G, Anikster Y, Abraham S, Segev R, et al. Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis. 2007;30:202-8.
45. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J Clin Densitom. 2013;16:455-66.
46. Coakley KE, Douglas TD, Singh RH. Using predictive modeling to estimate bone mineral density in children and adults with phenylketonuria. Osteoporosis International 2013, Conference: Interdisciplinary symposium on osteoporosis 2013 - Patient-centered care: Developing successful bone health teams, ISO 2013 Chicago, IL United States. Conference start: 20130418. Conference end: 20130421. Conference publication. S431-S432.
47. Ried K. Interpreting and understanding meta-analysis graphs-a practical guide. Aust Fam Physician. 2006;35:635-8.
48. Porta F, Roato I, Mussa A, Repici M, Gorassini E, Spada M, et al. Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria. J Inherit Metab Dis. 2008;31 Suppl 2:S339-42.
49. Tuchman S, Thayu M, Shults J, Zemel BS, Burnham JM, Leonard MB. Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr. 2008;153:484-90.
50. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92:443-9.
51. Greeves LG, Carson DJ, Magee A, Patterson CC. Fractures and phenylketonuria. Acta Paediatr. 1997;86:242-4.
52. Cosman F, de Beur SJ, Le Boff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-81.
53. Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. South Med J. 2009;102:175-9.